AFCR News

Global Coalition for Adaptive Research’s Innovative Clinical Trial Platform Opens to Evaluate New Therapies for Brain Cancer

The Global Coalition for Adaptive Research (GCAR) announced today that the GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) clinical trial is opening its first clinical site, the Henry Ford Cancer Institute, and will begin enrolling patients this week. GBM AGILE is the world’s first global adaptive clinical trial platform for glioblastoma (GBM), and will ultimately evaluate multiple therapies simultaneously across trial sites on multiple continents for patients with newly diagnosed and recurrent GBM – the deadliest brain cancer. Key strategic partners for the GBM AGILE Trial effort include the National Brain Tumor Society, National Foundation for Cancer Research, and Asian Fund for Cancer Research, three nonprofit organizations that are working together to provide philanthropic support as well as assistance in communicating with patients and families and inviting all others to join in supporting this innovating approach to brain tumor treatment development.

To read the original article, please click: https://www.businesswire.com/news/home/20190619005230/en/Global-Coalition-Adaptive-Researchs-Innovative-Clinical-Trial